Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Cash at Beginning of Period

Last Annual Value

3.09M

3-Year CAGR

-46%

5-Year CAGR

%

10-Year CAGR

%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Cash at Beginning of Period

ANEB · NASDAQ
CompanyCash at Beginning of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.09M
-40.3%0.5%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
12.21M
-12.8%-27.1%N/A
17.68M
9.6%114.3%N/A
36.53M
-7.2%-8.3%N/A
14.01M
2.1%-3.7%-12.5%
58.65M
-19.5%-1.0%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
9.72M
159.1%135.4%N/A
71.72M
10.2%19.8%N/A
54.42M
10.4%23.0%32.7%
20.75M
-22.5%-20.9%N/A
38.79M
16.2%-24.4%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72